Optimizing CAR T Therapies for Gastric Cancer

Video

Hong Ma, senior vice president, clinical development, cancer immunotherapy, CARSgen, discussed data from a phase 1 trial of CT041.

“We are developing a technology called CycloCAR to try to address the challenges we are facing using CAR T targeting solid tumors, namely CAR T persistence. It also requires strong preconditioning and a lymphodepletion regimen. With CycloCAR, we arm the CAR T using interleukin-7 CCR 21. Hopefully this improves the T cell persistence, and we have some preclinical data that show in animal models, you may not require lymphodepletion anymore.”

CARSgen is developing a next-generation chimeric antigen receptor (CAR) T-cell therapy, CT041, designed to combat challenges with traditional CAR T-cell therapies, namely cell persistence and lymphodepletion requirements. The company’s new technology, termed CycloCAR, which stands for cytokine and chemokine loaded CAR, is designed for increased T-cell recruitment, survival, and proliferation.

Results from a phase 1 trial (NCT03874897) of CT041 in gastric cancer were presented at the 7th Annual CAR-TCR Summit 2022 and were previously published in Nature Medicine. Overall response rate (ORR) was 48.6% and disease control rate (DCR) was 73.0%. The 6-month duration of response rate was 44.8%. No grade 3 or higher CRS or neurotoxicities, treatment-related deaths or dose-limiting toxicities were reported.

CGTLive spoke with Hong Ma, senior vice president of clinical development for cancer immunotherapy, CARSgen, to learn more about the advantages of CT041 in treating solid tumors. He discussed data from the phase 1 trial and next steps for the therapy.

REFERENCES
1. Ma H. CLDN18.2-targeted CAR T-cell therapy CT041 in subjects with cancers of the digestive system. Presented at: 7th Annual CAR-TCR Summit 2022, September 19-22, Boston, MA.
2. Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results. Nat Med. 28, 1189–1198 (2022). doi.org: 10.1038/s41591-022-01800-8
Related Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
© 2024 MJH Life Sciences

All rights reserved.